GlaxoSmithKline News and Research

RSS

Novartis earns global CEO Cancer Gold Standard accreditation

Novartis International AG, a multinational healthcare company headquartered in Basel, Switzerland, is the first company to earn global CEO Cancer Gold Standard accreditation. Their commitment to workplace wellness reaches across the globe to positively affect the lives of all their employees.

8 Aug 2013

GSK gets green light from FDA to ship Fluarix Quadrivalent influenza vaccine to healthcare providers

GlaxoSmithKline announced today it has received U.S. Food and Drug Administration approval to start shipping 2013-2014 FLUARIX QUADRIVALENT (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This is the first season that vaccines protecting against more than three strains of influenza (flu) will be commercially available.

6 Aug 2013

Protein linked to learning induces cocaine addiction, say researchers

A team of researchers says it has solved the longstanding puzzle of why a key protein linked to learning is also needed to become addicted to cocaine. Results of the study, published in the Aug. 1 issue of the journal Cell, describe how the learning-related protein works with other proteins to forge new pathways in the brain in response to a drug-induced rush of the “pleasure” molecule dopamine.

2 Aug 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Compliance leaders give insight and thoughts in new ebook

Regulatory non compliance costs the pharma industry billions in fines, audits and much more each year. To avoid these fines and bad reputation pharma companies rely heavily on their compliance teams, who provide oversight from R&D to the very end of a product cycle.

26 Jul 2013

Scientists reveal new images of how white blood immune cells attack tumours, viral infections

Scientists from The University of Manchester have revealed new images which provide the clearest picture yet of how white blood immune cells attack viral infections and tumours.

From The University of Manchester 24 Jul 2013

Actavis’ Lamictal ODT drug receives FDA approval for treatment of epilepsy and bipolar disorder

Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal® ODT.

16 Jul 2013

London research fellow says clinical study reports and trial results should be shared publicly

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

12 Jul 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

Increasing red meat intake boosts risk of type-2 diabetes mellitus

Eating more red meat over time is associated with an increased risk of type-2 diabetes mellitus (T2DM) in a follow-up of three studies of about 149,000 U.S. men and women, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication.

18 Jun 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

Renaissance in drug development for rare diseases

Once famously described as "orphan diseases, too small to be noticed, too small to be funded" in the Hollywood drama Lorenzo's Oil, rare diseases are getting unprecedented attention today among drug manufacturers, who are ramping up research efforts and marketing new medicines that promise fuller lives for children and other patients with these heartbreaking conditions.

14 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

Blog examines drug donation programs, Big Pharma's role in public health agenda

"Drug donations, reinvestment of profits in developing countries and a more flexible approach to intellectual property have all signaled a more collaborative approach from industry with the likes of GlaxoSmithKline, Sanofi, Johnson & Johnson and Merck all performing well in the 2012 Access to Medicine Initiative," Adam Robert Green, senior reporter with the Financial Times' "This is Africa," writes in the Royal African Society's "African Arguments" blog.

2 May 2013

2013 GSK IMPACT Awards Call for Applications issued

GlaxoSmithKline and Triangle Community Foundation today issued the 2013 GSK IMPACT Awards Call for Applications. This annual awards program will honor up to ten local nonprofits in Research Triangle Park, NC and the surrounding region with $40,000 each in recognition of their achievements and innovations in improving community health.

19 Apr 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013